PRECISION BIOSCIENCES INC
For the period ended Mar 12, 2026. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 12, 2026 · Filed Mar 12, 2026
Use the contents to explore the available documents and sections.
DTIL$10.60+7.4%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · PBGENE-NVS (Gene Insertion Program)
PBGENE-NVS (Gene Insertion Program)
As previously reported in October 2025, Novartis and Precision have concluded their work in the area of hemoglobinopathies. Precision and Novartis are continuing their research collaboration in other areas of undisclosed therapeutic focus.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.